Marathon Capital Management Makes New $3.19 Million Investment in Novo Nordisk A/S $NVO

Marathon Capital Management purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 57,475 shares of the company’s stock, valued at approximately $3,189,000.

Other hedge funds have also made changes to their positions in the company. True Wealth Design LLC boosted its position in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S during the third quarter valued at approximately $25,000. Strengthening Families & Communities LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter worth $30,000. Allianz SE boosted its holdings in Novo Nordisk A/S by 70.0% during the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after acquiring an additional 238 shares during the period. Finally, Financial Life Planners bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $33,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Novo Nordisk A/S Trading Down 0.1%

Shares of NVO stock opened at $37.99 on Friday. The firm has a fifty day moving average of $50.14 and a 200-day moving average of $51.79. The stock has a market cap of $169.61 billion, a price-to-earnings ratio of 10.95 and a beta of 0.73. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $82.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Wall Street Analyst Weigh In

NVO has been the subject of several recent analyst reports. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective on the stock. in a research note on Tuesday. Finally, Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Four analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $49.93.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.